Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. Read more about Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. Read more about Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Read more about Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. Read more about Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Read more about Immunotherapy for early triple negative breast cancer: research agenda for the next decade.
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Read more about Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ. Read more about The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study. Read more about The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Read more about Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? Read more about Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
